AstraZeneca is partnering with Boston Properties to create a 570,000-sf R&D center in Cambridge, Mass. Strategically sited in the Kendall Square life sciences district, the 16-story building will offer leading-edge lab environments for the discovery of new biomedical therapies and vaccines. Accommodating a total of 1,500 employees, the leased facility will also house the corporate headquarters of Alexion Pharmaceuticals, a subsidiary of AstraZeneca. Designed by Pickard Chilton, the highly efficient structure is expected to attain LEED Platinum sustainable design certification. Occupancy is expected in 2026.